Antigenic peptides and adjuvant CpG B-ODN emulsified in the mineral oil-based Incomplete Freund Adjuvant (IFA) is currently one of the most potent vaccine formulations for promoting the expansion of ex vivo-detectable tumor antigen-specific CD8 T-cell responses in melanoma patients (5, 6). Here, CD8A is linked to melanoma.